Keep up-to-date with the latest developments in IBD research by signing up to receive our 'Moving-On' newsletter.  A selection of recent articles is available below.



What is it like to live with inflammatory bowel disease in New Zealand?

Patient journey research: results

Atlantis Healthcare were asked by Janssen-Cilag (a pharmaceutical company) to talk to people living with IBD about their experiences.

Atlantis Healthcare talked to people living with IBD and the people who care for them – carers; gastroenterologists; nurses; a surgeon; a dietitian; and people from Crohn’s and Colitis New Zealand and the Ostomy Society

From this we tried to capture what it’s like to live with IBD from a medical; physical; psychological and social perspective. This is called a Patient Journey

How do we identify the bad guys driving inflammatory bowel disease?

As late as the 19th century we still believed in miasma – that infectious diseases travelled on ‘foulsome air’. The word malaria literally translates as bad air. Robert Koch and Louis Pasteur then defined the germ theory, that specific microbes cause specific diseases; revolutionising the treatment of infectious disease. Antibiotics together with vaccination and increased hygienic practices have resulted in a marked reduction in the morbidity and mortality of infectious diseases; and to date remain one of the only measures that can eradicate established disease. Concomitantly however, there has been a rapid rise in allergy, cancer, obesity, diabetes and inflammatory bowel disease (IBD), now known as ‘the secret killers’ of the modern world. These diseases have reached epidemic proportions and, for the first time, they are reversing the increase in life expectancy that has been achieved over the last century. 

Until recently, we have neglected beneficial gut microbiota and their interactions with the immune system in our quest to understand and treat these new immune mediated diseases. For too long we have considered gut microbiota simply as co-living organisms residing in the gut lumen. Our gut is an ecosystem housing trillions of microbes, with ten times the number of cells and over 100 times the number of genes when compared to the human body. Through recent cutting edge discoveries we now recognise the gut microbiota co-evolves in a mutualistic relationship with its host, a crucial event that impacts the function of the host’s immune system. Indeed, the absence of gut microbial colonisation results in a poorly developed immune system and high susceptibility to infectious pathogens. 

While the gut microbiota provides many benefits to the host, it requires strict immune control to maintain intestinal health. Imbalances of gut microbiota are associated with a number of disease states including allergic responses, adiposity, the formation of tumours, and intestinal inflammation such as IBD. A number of immune defence mechanisms contribute to control the location and composition of the gut microbiota and regulate immune responses in the intestine. Of these, immunoglobulin A (IgA) is an antibody that plays a critical role in the intestine. The main function of IgA is immune exclusion, preventing bacteria from reaching the epithelial cells. It also has an important role in both neutralising pathogenic bacterial antigens and toxins, and to nourish gut microbiota to maintain health. IgA deficiencies have been linked to microbial dysbiosis and increased intestinal inflammation. A new study now suggests the potential of identifying specific gut microbiota that promote an inflammatory state by assessing the degree to which IgA coats these bacteria1

These authors hypothesised that specific gut microbiota responsible for promoting intestinal inflammation in IBD could be identified by the degree to which they are coated with IgA. Stool samples from 27 patients with Crohn’s disease (CD) and 8 patients with ulcerative colitis (UC) were compared to 20 healthy controls. These investigations identified that the percentage of IgA-coated gut microbiota in the CD and UC patients was significantly increased relative to healthy controls. Thirty-five gut microbiota species were highly coated with IgA in IBD patients. While some of these species were also present in the stool from healthy controls, they were not coated with IgA. 

Sophisticated culture techniques were then employed to generate gut microbiota samples from both IgA and non-IgA bound gut microbiota communities from faecal samples of 11 IBD patients. These faecal samples were then transplanted into germ free mice, which are mice that lack any living viruses, bacteria or fungi. When these mice were exposed to intestinal injury, the mice that had been colonized with the IgA coated gut microbiota developed significant intestinal inflammation that resembles ulcerative colitis in patients. Conversely, the mice exposed to the non-IgA coated gut microbiota had markedly less intestinal inflammation. 

These findings now suggest that IgA coating could potentially identify inflammation associated gut microbiota in patients with IBD. More research needs to occur to address the following questions. Are there more than the 35 identified IgA bound gut microbiota species to be found in a larger number of IBD patients? Do patients in clinical remission have less IgA-coated gut microbiota as compared to when they were first diagnosed with disease, or their last disease flare? Most importantly, can we target these IgA coated gut microbiota without affecting the rest of the gut microbiota community needed for health? This represents a major challenge, and it is likely this approach may be applicable to only a subset of IBD patients. Yet such a possibility represents an exciting breakthrough for IBD, and may provide a novel approach to disease treatment.

By Dr Liz Forbes-Blom, PhD,

Malagan Institute

  1. Palm NW, de Zoete MR, Cullen TW, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell. 2014;158(5):1000-1010.

Faecal Calprotectin

You may have heard about a test that is relatively new called a stool or faecal calprotectin level. It is a test that measures a protein called calprotectin in the stool.

What is calprotectin?
Calprotectin is a protein that is found in white blood cells, the cells that are involved in causing inflammation in the body. Since there is an increased number of white blood cells in the intestines of people who have active IBD, measurement of the stool calprotectin level can be used as a marker of inflammation.

How good a test is it?
Calprotectin is a very good marker of inflammation, but, like any test, there can be false negative and false positive results. In one study in patients with Crohn’s disease, however, it correlated much better with the inflammation seen on colonoscopy than some of the  tests that we currently use like the CRP and the Crohn’s Disease Activity Index (CDAI).

How can the test be used?
Some people propose that it can be used as a screening test in people with symptoms suggestive of IBD (such as diarrhoea and abdominal pain) to determine if they should undergo a colonoscopy (particularly in children in whom we might want to avoid doing the procedure). Others have suggested that it can be used as an objective measure (rather than relying on symptoms alone) to see if people are responding to their medications.

Are there conditions other than IBD that can cause an elevated calprotectin level?
Yes. Calprotectin levels can be raised in ANY condition which causes intestinal inflammation (such as infections).

Is the test accurate?
While the cutoff for a normal test is <50 mcg/g stool, there is a “gray zone” where higher levels may or may not be significant. A very high level (>500) correlates very well with active inflammation.

How you do the test?
It is very simple. You just have to bring in a stool sample (you only need a few grams). Calprotectin is very stable so the specimen does not need to be refrigerated or brought immediately to the lab.

Is it expensive?
It costs about $150, but price varies from  lab to lab. Most DHBs cover the test.

How come I never had the test done?
This is just one test that doctors can use, but it cannot replace a thorough history and physical examination. In most situations, it is not a necessary test to determine the best treatment, but it may have a place in the situations mentioned above. As usual, more studies need to be done to best determine how to use this test.

A new drug on the horizon

Immune cell migration into an organ such as the intestine is a tightly regulated process, involving a network of chemical messengers and cell adhesion molecules. The chemical messengers instruct the immune cells to migrate into the intestine and the cell adhesion molecules allow them to get in. 

These cellular adhesion molecules do so by interacting with a ligand specific to the intestine. So, the cell adhesion molecule is like a key and its ligand is similar to a lock. 

In the intestine, the integrin ‘key’ is called alpha-4 beta-7 (also known as α4β7) and the ligand or ‘lock’ is mucosal addressin cell adhesion molecule 1 (or MAdCAM-1 for short). 

Just like the key/lock analogy, each integrin is specific for its ligand. Therefore, the ability to interrupt the migration of inflammatory cells by targeting the specific key is highly desirable, as this generates very precise intervention at the site of inflammation. 

Vedolizumab is an antibody that targets the intestine specific integrin α4β7, effectively preventing it from being able to ‘unlock’ intestinal inflammation. Excitingly, the results from the phase III clinical trial of Vedolizumab have shown this antibody to be effective both in the reduction and in the maintenance of remission of ulcerative colitis. Specifically, 47.1% of patients on Vedolizumab compared with 25.5% on placebo showed a clinical response at week 6 of the induction regimen, and 16.9% compared with 5.4% were already exhibiting clinical remission at that time point [1].  Maintenance treatment with 4-weekly Vedolizumab resulted in 44.8% of patients being in remission at the 52-week time point compared with 15.9% on placebo [1]. 

The results from the Crohn’s disease trial were also very hopeful. The primary endpoint of clinical remission at 6 weeks was not reached, however, there were significantly more patients on Vedolizumab in clinical remission at this time point compared with placebo-treated patients [2]. This included 39% on 8-weekly Vedolizumab, 36.4% on 4-weekly Vedolizumab, as compared to 21.6% on placebo were in clinical remission at week 52 [2]. 

There are many possible explanations as to why Vedolizumab was so remarkably effective as a therapeutic for the ulcerative colitis trial, yet did not reach clinical remission at 6 weeks during the Crohn’s disease trial. These include different kinetics of therapy in Crohn’s disease compared with ulcerative colitis, or the possibility α4β7 integrin might be required for immune cells that drive remission of Crohn’s disease to also migrate to the intestine. 

Further studies are warranted to fully understand what is going on.

By Dr. Liz Forbes-Blom, PhD

Malagan Institute 

1          Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J. F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H. J., Danese, S., Fox, I., Milch, C., Sankoh, S., Wyant, T., Xu, J. and Parikh, A., Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine 2013. 369: 699-710.

2          Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J. F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., Fox, I., Rosario, M., Sankoh, S., Xu, J., Stephens, K., Milch, C. and Parikh, A., Vedolizumab as induction and maintenance therapy for Crohn's disease. The New England journal of medicine 2013. 369: 711-721.




+ Text Size -
Original generation time 1.1397 seconds.